å·®å«
è¿éä¼æ¾ç¤ºåºæ¨éæ©ç修订çåå
两侧同时换到之前的修订记录 前一修订版 后一修订版 | 前一修订版 | ||
其他:英文缩写汇总 [2022/11/02 06:52] test1 [N] |
其他:英文缩写汇总 [2023/11/03 11:21] (当前版本) Fei Song [N] ~[Z] 仅调整了格式 |
||
---|---|---|---|
行 67: | 行 67: | ||
^缩写^全称^中文| | ^缩写^全称^中文| | ||
- | |HBsAG|Hepatitis B surface Antigen|乙型肝炎表面抗原| | + | |HBsAg|Hepatitis B surface Antigen|乙型肝炎表面抗原| |
|HLGT|High Level Group Term|高级别组术语| | |HLGT|High Level Group Term|高级别组术语| | ||
|HLV|High Level Term|高级别术语| | |HLV|High Level Term|高级别术语| | ||
|HIV|Human Immunodeficiency Virus|人类免疫缺陷病毒| | |HIV|Human Immunodeficiency Virus|人类免疫缺陷病毒| | ||
|HT|Included terms|收录术语| | |HT|Included terms|收录术语| | ||
+ | |||
==== I ==== | ==== I ==== | ||
行 120: | 行 121: | ||
|[[https:// | |[[https:// | ||
- | // ==== O ==== ^缩写^全称^中文| | | ==== P ==== ^缩写^全称^中文|PBO|Placebo|安慰剂| PK |Pharmacokinetic(s)|药代动力学|PD|Pharmacodynamics|药效学|PPS|Per-Protocol Set|符合方案集|PRO|Patient Reported Outcome|患者报告结局|PSOC|Primary System Organ Class|主要系统器官类|PT|Preferred Term|首选术语| | + | ==== O ==== |
- | // // | + | ^缩写^全称^中文| |
+ | | | | | ||
- | //// | + | ==== P ==== |
+ | ^缩写^全称^中文| | ||
+ | |PBO|Placebo|安慰剂| | ||
+ | |PK |Pharmacokinetic(s)|药代动力学| | ||
+ | |PD|Pharmacodynamics|药效学| | ||
+ | |PPS|Per-Protocol Set|符合方案集| | ||
+ | |PRO|Patient Reported Outcome|患者报告结局| | ||
+ | |PSOC|Primary System Organ Class|主要系统器官类| | ||
+ | |PT|Preferred Term|首选术语| | ||
+ | ==== Q ==== | ||
+ | |||
+ | ^缩写^全称^中文| | ||
+ | |q.d.|Once Daily|每日一次| | ||
+ | |||
+ | ==== R ==== | ||
+ | |||
+ | ^缩写^全称^中文| | ||
+ | |RA|Rheumatoid Arthritis|类风湿性关节炎| | ||
+ | |RBC|Red Blood Cell|红细胞| | ||
+ | |RDC|Remote Data Acess|远程数据获取| | ||
+ | |||
+ | ==== S ==== | ||
+ | |||
+ | ^缩写^全称^中文| | ||
+ | |SAE|Serious Adverse Event|严重不良事件| | ||
+ | |SAP|Statistical Analysis Plan|统计分析计划| | ||
+ | |SAR|Statistical Analysis Reoort|统计分析报告| | ||
+ | |SC|Study Coordinator|临床研究协调者| | ||
+ | |SD|Standard Deviation|标准差| | ||
+ | |SD|Source Data/ | ||
+ | |SDV|Source Data Verification|原始数据核准| | ||
+ | |SFU|Safety Follow-Up (Visit)|安全性随访| | ||
+ | |SOC|System Organ Class|系统器官分类| | ||
+ | |SOP|Standard Operating Procedure|标准操作规程| | ||
+ | |SS|Safety Set|安全性数据集| | ||
+ | |SUSAR|Suspected Unexpected Serious Adverse Reaction|可疑非预期严重不良反应| | ||
+ | |||
+ | ==== T ==== | ||
+ | |||
+ | ^缩写^全称^中文| | ||
+ | |TB|Tuberculosis|结核病| | ||
+ | |TEAE|Treatment-Emergent Adverse Event|治疗引发的不良事件| | ||
+ | |TIA|Transient Ischemic Attack|短暂性脑缺血发作| | ||
+ | |t.i.d|Three Times a Day|每日三次| | ||
+ | |TNF|Tumor Necrosis Factor|肿瘤坏死因子| | ||
+ | |||
+ | ==== U ==== | ||
+ | |||
+ | ^缩写^全称^中文| | ||
+ | |UAT|User Acceptance Testing|用户接受测试| | ||
+ | |ULN|The Upper Limit of Normal Value|正常值上限| | ||
+ | |||
+ | ==== V ==== | ||
+ | |||
+ | ^缩写^全称^中文| | ||
+ | | | | | ||
+ | |||
+ | ==== W ==== | ||
+ | |||
+ | ^缩写^全称^中文| | ||
+ | |[[https:// | ||
+ | |WHO DDE|WHO Drug Dictionary Enhanced|世界卫生组织药物词典增强版| | ||
+ | |WHO HD|WHO Herbal Dictionary|世界卫生组织草药词典| | ||
+ | |WD|Withdrawal|退出| | ||
+ | | | | | ||
+ | |||
+ | ==== X ==== | ||
+ | |||
+ | ^缩写^全称^中文| | ||
+ | | | | | ||
+ | |||
+ | ==== Y ==== | ||
+ | |||
+ | ^缩写^全称^中文| | ||
+ | | | | | ||
+ | |||
+ | ==== Z ==== | ||
+ | |||
+ | ^缩写^全称^中文| | ||
+ | | | | |